Key Highlights
• Microbot Medical (NASDAQ: MBOT) enters manufacturing agreement with Sanmina to expand LIBERTY® Endovascular Robotic System production.
• The collaboration is intended to satisfy anticipated demand from both current and prospective customers while aiding cost‑reduction initiatives.
• Agreement filed with the U.S. Securities and Exchange Commission on June 30, 2026.
• Forward‑looking statements carry risks, with no obligation to update projections under the Securities Exchange Act of 1934.
Microbot Medical (NASDAQ: MBOT) has entered into a production partnership aimed at accelerating the build‑out of its LIBERTY robotic platform. By joining forces with Sanmina, the company seeks to broaden its manufacturing footprint and improve overall efficiency.
Expanding Production Capacity
Under a Letter of Agreement, Sanmina will assume responsibility for fabricating the LIBERTY Endovascular Robotic System. This arrangement is designed to enlarge output levels, positioning Microbot to respond to projected market needs.
Emphasis on Cost Management
The joint effort aligns with Microbot’s strategy to lower expenses. Leveraging Sanmina’s established facilities allows the firm to streamline its supply chain while preserving the high standards required for medical‑device quality.
SEC Filing Information
Details of the partnership were disclosed in a filing with the U.S. Securities and Exchange Commission dated June 30, 2026. The submission outlines the core terms of the manufacturing alliance, without guaranteeing specific performance metrics.
Caution Regarding Projections
Statements concerning future demand and potential cost benefits are forward‑looking and subject to numerous uncertainties. The company does not commit to revising these outlooks unless mandated by applicable securities regulations.
Points for Investors
Stakeholders are encouraged to examine all relevant disclosures, including risk factors highlighted in Microbot’s SEC documents. The manufacturing tie‑up reflects an effort to reinforce the company’s standing within the endovascular robotics arena.
Implications for the Market
By securing Sanmina’s manufacturing expertise, Microbot may enhance its ability to compete in the expanding medical‑robotics field. The partnership is expected to improve production reliability and scalability for the LIBERTY system.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...